Studies molecular changes in metastatic breast cancer using biopsies and blood
Studies tumor changes and treatment resistance in adults with spreading breast cancer.
Plain-language title generated from the registry record
Registry title: Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)
Key facts
- Where
- Lund, SwedenSee the site
Where in Sweden
- Lund University HospitalLund, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lund University Hospital
- Trial code
- NCT03758976
- Record updated
- 16 September 2025
- Original description
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure.Read full original descriptionShow less
SCAN-B-rec: Infrastructure, Technology Platform and Clinical Research Development to Profile and Monitor Metastatic Breast Cancer
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure.
The main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response/resistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.
Inclusion: Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease; Age > 18 years; Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2; ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET); Patients must have a radiological evaluation done maximum 6 weeks prior to inclusion; Signed informed consent according to ICH/GCP, and national/local regulations.
Exclusion: Untreated psychiatric disorders that will impair the patient's ability to comply with study treatment or protocol.